Blog to serve as a resource on issues and topics related to chronic
pain, such as digital medicine and alternative treatments
WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix,
Inc. (Nasdaq: NURO) today announced the launch of LivingQuell,
a blog that will serve as an online resource for people affected by
chronic pain - as well as the rapidly growing user base of the company's
Quell® Wearable Pain Relief Technology™.
With an estimated one in three Americans living with chronic pain,
NeuroMetrix aims to create an online space to share new ideas and
content, and bring together all who are impacted. LivingQuell will cover
a variety of topics for those living with pain, their loved ones,
caregivers, clinicians and beyond. It will also include perspectives on
industry news, viewpoints from pain management and sleep healthcare
professionals, and real stories from Quell users. Blog readers can also
expect to learn about alternative treatments to opioids and emerging
drug-free therapies, which are becoming more essential to managing
chronic pain.
"Over the last 20 years at NeuroMetrix, we've maintained the practice of
being customer-centric. We listen to our users and make improvements to
our products in response to their feedback," said Shai N. Gozani, M.D.,
Ph.D., President and CEO of NeuroMetrix. "A blog that supports our
customers in new ways with content from their peers as well as experts
was a logical next step in our mission. Our hope is for LivingQuell to
bring greater awareness, insight and education to the broader chronic
pain conversation and to Quell users."
Alongside the launch of the LivingQuell blog, NeuroMetrix is also
introducing a Quell Ambassador program. "We regularly connect with our
users and chronic pain influencers, and they all have unique experiences
and perspectives to share," said Frank McGillin, Senior Vice President
and Chief Commercial Officer at NeuroMetrix. "Our Ambassador program
offers a new way for them to participate in important conversations and
share their personal stories about chronic pain. This also allows users
whose lives have been impacted by Quell to influence future decisions
about product innovation."
Recently, NeuroMetrix welcomed a group of 30 users local to its Waltham,
Mass. headquarters to "meet the makers," learn about upcoming Quell
product features and share their stories and feedback on the product.
Quell users were able to learn more about product development directly
from Dr. Gozani, and connect with peers and NeuroMetrix's customer care,
engineering and marketing teams. Through the Quell Ambassador program,
NeuroMetrix intends to host more of these events.
LivingQuell is now live at blog.quellrelief.com.
Quell users interested in joining the Ambassador program can sign up by
visiting https://www.quellrelief.com/ambassador/.
About Quell
Quell is designed for millions of people
suffering from chronic pain. The advanced wearable device is lightweight
and can be worn during the day while active, and at night while
sleeping. It has been cleared by the FDA for treatment of chronic pain
without a prescription. In a recent study, 81% of Quell users reported
an improvement in their chronic pain. Quell users can personalize and
manage therapy discreetly via the Quell Relief app. Quell also offers
advanced health tracking relevant to chronic pain sufferers including
pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW
(South by Southwest) Innovation Award for Best Wearable Technology.
Quell is available at select healthcare professionals and retailers.
Visit QuellRelief.com
for more information.
About NeuroMetrix
NeuroMetrix is a commercial stage,
innovation driven healthcare company combining bioelectrical and digital
medicine to address chronic health conditions including chronic pain,
sleep disorders, and diabetes. The company's lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain. Quell is
integrated into a digital health platform that helps patients optimize
their therapy and decrease the impact of chronic pain on their quality
of life. The company also markets DPNCheck®, a rapid
point-of-care test for diabetic neuropathy, which is the most common
long-term complication of Type 2 diabetes. The company maintains an
active research effort and has several pipeline programs. The company is
located in Waltham, Massachusetts and was founded as a spinoff from the
Harvard-MIT Division of Health Sciences and Technology in 1996. For more
information, please visit NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170516005080/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
